They have no fiduciary duty in many cases and can profit from customers’ confusion. But where’s the line between unsavory and illegal?

Truist Financial upgraded shares of Pacira BioSciences (NASDAQ:PCRX – Free Report) from a sell rating to a hold rating in a research report sent to investors on Thursday morning, MarketBeat reports.

Bank stocks have had a solid January, and regional-bank stocks, and the ETF, look set to rise for the rest of the year.

In summary, the upgrade in the price target to $675 from $665 by Truist Securities reflects the firm's confidence in Roper ...

In a report released today, Youssef Squali from Truist Financial maintained a Buy rating on DoubleVerify Holdings (DV – Research Report). The ...

Bank of America Securities analyst Ebrahim Poonawala maintained a Buy rating on US Bancorp (USB – Research Report) today. The company’s shares ...

The analysts also believe that Seacoast Banking (NASDAQ:SBCF) could engage in capital deployment activities, including ...

The San Antonio insurance and financial services company didn’t specify how much in financial damages it is seeking from ...

Synchrony Financial's fourth-quarter earnings results missed analysts' forecasts and investors pummeled the stock due to a ...

USAA claims to have developed the mobile capture deposit technology and has already successfully sued Discover and Truist, ...

Truist analyst Michael Ciarmoli initiated coverage of Northrop Grumman Corp. NOC and Lockheed Martin Corp LMT with buy ratings because recent drops in their stock prices present a buying opportunity.

If the General Services Administration becomes a target for cost cuts, the shift could impact markets both within and outside ...